Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Zinier fields investors for $90m series C
Stanford-StartX's Zinier took its overall funding to $120m in a round that included returning investor Qualcomm Ventures, with the cash to go to international growth and product development.
Jasper grasps $50m
Jasper Therapeutics, based in part on Stanford research, has raised a $15m series A extension on the back of early clinical results from its blood transplant conditioning program.
Deep Genomics dives for $40m
Deep Genomics will use the money to advance drug candidates created through its AI drug development model, based on research by Toronto faculty.
Soul Machines personifies $40m series B
University of Auckland Inventors Fund has contributed to a $40m series B round for AI-based avatar developer Soul Machines, with the investment led by Temasek. copies in $45m, a Memorial Sloan Kettering spinout, has obtained more than $70m to date and will use the series B to expand its market presence and product line.
Promethera protracts series D round
Medipal and Sony Innovation Fund by IGV were among the investors that boosted the liver disease drug spinout's latest round to $52.6m.
LandSpace embraces $71m
Space rocket producer LandSpace, a Tsinghua University spinout, has now raised about $200m in all from investors including Xidian University and 36kr Media.
Roche polishes Black Diamond's $85m series C
The cancer drug developer emerged from stealth with $194m in funding, $85m of which was just closed in a round featuring returning investor Roche Venture Fund.

Other News

Duolingo converses with CapitalG for $30m
Carnegie Mellon University's language teaching app Duolingo has received series F funding from existing backer CapitalG and is now valued at $1.5bn.
Limelight shines in $75m round
Gene therapy developer Limelight Bio grew from research at University of Pennsylvania and has landed $75m in its first publicly-disclosed round.
ImCheck imports $53m in series B cash
Pfizer Ventures led the immuno-oncology drug developer's latest round, which was spun out of Institut Paoli-Calmettes with the help of Satt Sud-Est and Inserm Transfert.
Azeria erects $42.2m series B
Azeria Therapeutics has picked up Syncona as an investor as it looks to bring its therapy for receptor-positive luminal breast cancer into the clinic.
Tissium grafts $42.8m
MIT-founded regenerative polymer developer Tissium will put the capital into clinical-stage development and toward regulatory clearance in multiple markets.
PMV pinpoints $62m investment
OUP returned for PMV's series C round which the company will use to cement its portfolio of small molecule treatments targeting cancerous p53 mutations.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg